The Scientific Frontier

Disease Modifying Therapy

1 article

Young child with a hopeful expression, symbolizing the positive impact of Tzield on delaying type 1 diabetes onset in pediatric patients.
Cosmos & Physics

FDA Approves Sanofi's Tzield for Type 1 Diabetes in Children

For the first time, a disease-modifying therapy is now available to delay the onset of type 1 diabetes in children as young as one year old.

Dr. Evelyn Reed·June 14, 2026